NCT07333885

Impact of Reducose® on Glycemic Response and Menopausal Symptoms in Perimenopausal Women (CALM-R)

The Impact of Reducose® on Symptoms of Perimenopause and Glycemic Response: a Randomized Controlled Trial

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Phynova Group Ltd · Industry
• Sex: Female
• Age: 40 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of this double-blind, randomized, placebo-controlled trial is to. evaluate daily Reducose® (mulberry leaf extract) supplementation taken with the two largest meals for 12 weeks on improving glycemic response and perimenopausal symptoms in women aged 40-60 years. Glycemic response is measured using Dexcom Stelo continuous glucose monitors during standardized test meals, and menopausal symptoms and sleep/quality-of-life outcomes are assessed using validated surveys administered through the Chloe app in a decentralized U.S. study.

Conditions

• Glycemic Response
• Menopause Symptoms

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Reducose® (Mulberry leaf extract)	Reducose® proprietary mulberry leaf extract, 250mg, 2/day with meals
DIETARY_SUPPLEMENT	Placebo	Placebo matching capsules, Microcrystalline Cellulose

Timeline

• Start date: 2025-12-12
• Primary completion: 2026-06-01
• Completion: 2026-08-01
• First posted: 2026-01-12
• Last updated: 2026-01-12

Locations

1 site across 1 country: United States